Impairment of regulatory T cells in myasthenia gravis: Studies in an experimental model

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 894-903

  Gertel Lapter, Smadar ^a,b   Mizrachi, Keren ^a,c   Berrih Aknin, Sonia ^d   Fuchs, Sara ^a   Souroujon, Miriam C ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b OPEN UNIVERSITY OF ISRAEL   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

EAMG; Myasthenia gravis; Regulatory T cells

Indexed keywords

FREUND ADJUVANT; INTERLEUKIN 17; LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR FOXP3;

APOPTOSIS; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL EVALUATION; COMPARATIVE STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NONHUMAN; POLYMERASE CHAIN REACTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVIEW; RNA ISOLATION;

ANIMALS; HUMANS; IMMUNE TOLERANCE; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; T-LYMPHOCYTES, REGULATORY;

EID: 84879190608     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.009     Document Type: Review

References (68)

1. Engel A.G., Lindstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 1977, 27:307-315.
2. Engel A.G., Tsujihata M., Lindstrom J.M., Lennon V.A. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci 1976, 274:60-79.
3. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
4. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12:931-935. (this issue).
5. Tüzün E., Christadoss P. Complement Associated Pathogenic Mechanisms in Myasthenia Gravis. Autoimmun Rev 2013, 12:904-911. (this issue).
6. Verschuuren J.J. HuijbersMG, Jaap J. Plomp, Erik H, Niks PC, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923. (this issue).
7. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12:924-930. (this issue).
8. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies againstmuscle-specific kinase inmyasthenia gravis. Autoimmun Reviews 2013, 12:912-917. (this issue).
9. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin Immunol 2000, 94:75-87.
10. Souroujon M.C., Fuchs S. Experimental autoimmune myasthenia gravis. Immunological Methods Manual 1997, 1763-1773. Academic Press. I. Lefkovitseds (Ed.).
11. Souroujon M.C., Brenner T., Fuchs S. Development of novel therapies for MG: studies in animal models. Autoimmunity 2010, 43:446-460.
12. Conti-Fine B.M., Milani M., Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 2008, 1132:193-209.
13. Elson C.J., Barker R.N. Helper T cells in antibody-mediated, organ-specific autoimmunity. Curr Opin Immunol 2000, 12(6):664-669.
14. Berrih-Aknin S., Le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B cell therapy in Myasthenia Gravis. Autoimmun Rev 2013, 12:385-393. (this issue).
15. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010, 225:123-131.
16. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
17. Hemdan N.Y., Birkenmeier G., Wichmann G., Abu El-Saad A.M., Krieger T., Conrad K., et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev 2010, 9:785-792.
18. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
19. Selmi C. Autoimmunity in 2010. Autoimmun Rev 2011, 10:725-732.
20. Miyara M., Gorochov G., Ehrenstein M., Musset L., Sakaguchi S., Amoura Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011, 10:744-755.
21. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
22. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
23. Shevach E.M. Regulatory T, cells in autoimmmunity*. Annu Rev Immunol 2000, 18:423-449.
24. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
25. Apostolou I., von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004, 199:1401-1408.
26. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
27. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257.
28. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
29. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
30. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
31. Shevach E.M., DiPaolo R.A., Andersson J., Zhao D.M., Stephens G.L., Thornton A.M. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 2006, 212:60-73.
32. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003, 112:1437-1443.
33. Sakaguchi S. Regulatory T, cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
34. Sakaguchi S., Toda M., Asano M., Itoh M., Morse S.S., Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun 1996, 9:211-220.
35. Sakaguchi S., Powrie F., Ransohoff R.M. Re-establishing immunological self-tolerance in autoimmune disease. Nat Med 2012, 18:54-58.
36. Hsu W.T., Suen J.L., Chiang B.L. The role of CD4CD25 T cells in autoantibody production in murine lupus. Clin Exp Immunol 2006, 145:513-519.
37. Iikuni N., Lourenco E.V., Hahn B.H., La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol 2009, 183:1518-1522.
38. Berrih-Aknin S., Morel E., Raimond F., Safar D., Gaud C., Binet J.P., et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci 1987, 505:50-70.
39. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:401-412.
40. Balandina A., Lecart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
41. Fattorossi A., Battaglia A., Buzzonetti A., Ciaraffa F., Scambia G., Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 2005, 116:134-141.
42. Wang X.B., Kakoulidou M., Giscombe R., Qiu Q., Huang D., Pirskanen R., et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002, 130:224-232.
43. Aricha R., Feferman T., Fuchs S., Souroujon M.C. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 2008, 180:2132-2139.
44. Aricha R., Mizrachi K., Fuchs S., Souroujon M.C. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011, 36:135-141.
45. Mu L., Sun B., Kong Q., Wang J., Wang G., Zhang S., et al. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009, 128:e826-e836.
46. Aharonov A., Tarrab-Hazdai R., Silman I., Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 1977, 14:129-137.
47. Lennon V.A., Lambert E.H., Leiby K.R., Okarma T.B., Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 1991, 146:2245-2248.
48. Zhao D.M., Thornton A.M., DiPaolo R.J., Shevach E.M. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006, 107:3925-3932.
49. Ludwig-Portugall I., Hamilton-Williams E.E., Gotot J., Kurts C. CD25+ T(reg) specifically suppress auto-Ab generation against pancreatic tissue autoantigens. Eur J Immunol 2009, 39:225-233.
50. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
51. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010, 10:849-859.
52. Dalakas M.C. Novel future therapeutic options in Myasthenia Gravis. Autoimmun Rev 2013, 12:936-941. (this issue).
53. Nessi V., Nava S., Ruocco C., Toscani C., Mantegazza R., Antozzi C., et al. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. J Immunol 2010, 185:5656-5667.
54. de Kleer I.M., Wedderburn L.R., Taams L.S., Patel A., Varsani H., Klein M., et al. CD4+CD25 bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004, 172:6435-6443.
55. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
56. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199:971-979.
57. Kriegel M.A., Lohmann T., Gabler C., Blank N., Kalden J.R., Lorenz H.M. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004, 199:1285-1291.
58. Chi L.J., Wang H.B., Zhang Y., Wang W.Z. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol 2007, 192:206-214.
59. Valencia X., Yarboro C., Illei G., Lipsky P.E. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007, 178:2579-2588.
60. Moulian N., Bidault J., Truffault F., Yamamoto A.M., Levasseur P., Berrih-Aknin S. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 1997, 89:3287-3295.
61. Koenen H.J., Smeets R.L., Vink P.M., van Rijssen E., Boots A.M., Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
62. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 2009, 106:4793-4798.
63. Weaver C.T., Hatton R.D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009, 9:883-889.
64. Clough L.E., Wang C.J., Schmidt E.M., Booth G., Hou T.Z., Ryan G.A., et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 2008, 180:5393-5401.
65. D'Alise A.M., Auyeung V., Feuerer M., Nishio J., Fontenot J., Benoist C., et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A 2008, 105:19857-19862.
66. Gregori S., Giarratana N., Smiroldo S., Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003, 171:4040-4047.
67. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13:423-431.
68. You S., Belghith M., Cobbold S., Alyanakian M.A., Gouarin C., Barriot S., et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005, 54:1415-1422.